ArticleFrontiers in oncology2020
Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Rigid crosslinking of the CD3 complex leads to superior T cell stimulation.Frontiers in immunology · 2024Article
- Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma.Scientific reports · 2023Article
- Multi-targeted immunotherapeutics to treat B cell malignancies.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?Journal of hematology & oncology · 2022Review
- Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis.American journal of cancer research · 2022Article
- Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.Frontiers in immunology · 2022Article
- Bispecific T Cell Engagers for the Treatment of Multiple Myeloma: Achievements and Challenges.Cancers · 2021Review
- Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma.Frontiers in oncology · 2021Review
- Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells.Frontiers in immunology · 2021Article
- Latest evidence on immunotherapy for cholangiocarcinoma.Oncology letters · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.